The RELIANCE Trial provided the first demonstration of licensure-quality CAR-T manufacturing and clinical trial data generation in r/r patients originating in China. These results with relma-cel demonstrate similar preliminary response rates and PK profiles while providing the potential for an improved toxicity profile in heavily-pre-treated patients with r/r DLBCL having poor risk features relative to other CD19-specific CAR-Ts approved in the US and EU.
药明巨诺(港交所代码:2126)是一家领先的细胞免疫治疗公司,由巨诺医疗(一家百时美施贵宝的公司)和药明康德联合创建。公司已建立了一个专注为血液及实体瘤开发、制造和商业化的突破性细胞免疫疗法的一体化平台。
药明巨诺致力于为中国市场开发创新的细胞治疗手段,改变中国患者的癌症治疗方式。公司已建立了涵盖血液及实体瘤的全面且差异化的细胞治疗产品管线。主打产品瑞基奥仑赛注射液是针对复发或难治B细胞淋巴瘤的靶向CD19的CAR-T疗法,有望成为中国首个获批1类生物制品的CAR-T疗法。

1186 Clinical Response of CD19 CAR-T Cells (relmacabtagene autoleucel, relma-cel) in Adults with Heavily-Pre-Treated Relapsed/Refractory (r/r) Large B-Cell Lymphoma in China

涵盖血液及实体肿瘤、全面且差异化的细胞治疗产品管线
我们战略性地搭建了差异化的细胞免疫疗法产品管线,涵盖多种提升产品效益风险比的全新一代疗法,包括异基因疗法、联合小分子药物疗法及其他新型基因改造的CAR-T产品。我们相信我们的在研产品有潜力成为各自适应症的突破性疗法。